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Background: For children requiring split-thickness skin grafting for burn injury, the optimum donor site dressing is
an ongoing subject of debate. The most common dressings in use, both regionally and worldwide, are calcium
alginates. We will compare an alginate with two other dressings, all of which are in current use in the Pegg
Leditschke Paediatric Burns Centre (PLPBC), to determine which dressing performs the best.
Methods/Design: This is a randomised, prospective single center parallel three-arm trial comparing three donor site
wound (DSW) dressings: Algisite™ M, a calcium alginate dressing; Cuticerin™, a smooth acetate gauze impregnated
with water-repellent ointment (petrolatum, paraffin and Eucerite®) and Sorbact®, a gauze mesh coated with a
dialkylcarbamoyl chloride (DACC) and amorphous hydrogel.
Primary outcomes are days to complete DSW healing, and pain. Previously validated measures will be used for all
outcomes. Secondary outcomes are: itch; scar appearance at three, six and 12 months; ease of dressing application and
removal and dressing costs and utility. Results will be analysed on an intention-to-treat basis. Donor site thickness will
be measured with a small biopsy from the center of the graft, to document the depth of the DSW across the groups.
Discussion: This study will provide comprehensive short- and long-term data on DSW dressings in pediatric
split-thickness skin grafting. The best-performing dressing will become the preferred dressing for the PLPBC.
We will provide rigorous data against which other dressings can be compared in future, recognising that
alginates are the most common DSW dressing currently in use. Our study design replicates a real-world
scenario in order to identify clinically significant differences between the three dressings.
Trial registration: This trial was prospectively registered on 8 April 2014 with the Australia and New Zealand
Clinical Trials Register (identifier: ACTRN12614000380695).
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Split-thickness skin grafting (STSG) is the most widely
used method of achieving skin coverage in burns that
are not predicted to heal rapidly with dressings. In har-
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unless otherwise stated.created, the donor site wound (DSW). In children, this
wound is predicted to re-epithelialise in seven to 14 days.
The ideal DSW dressing does not adhere to the wound
bed, facilitating removal. DSW dressings should be pain-
free, reduce blood loss and be changed infrequently;
ideally not until the wound has healed [1-4]. Among cli-
nicians, a pain-free dressing is the most consistently de-
sirable or essential quality of a wound dressing, in
recognition of the fact that the DSW is often more pain-
ful than the recipient site [5]. The need for such a dress-
ing is, if anything, more important in pediatric burn care
as there are data suggesting that decreased pain leads tol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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wound healing [6-8]. Additionally, rapid healing permits
the repeat harvesting of donor areas in larger burns and
also decreases the risk of scarring [9].
The optimum dressing for the DSW is unclear, with
surgeon and centre choice appearing to follow tradition
stemming from eminence as often as it follows selection
stemming from evidence. Alginates are the most com-
monly used DSW dressing [2,3]. There are four system-
atic reviews investigating DSW dressings [10-13], none
of which have identified a single dressing with a clearly
superior performance. Data are particularly lacking in
pediatric burns, and new dressings are being developed
continually. There is a clear need for high quality evi-
dence in pediatric DSW dressings.
Due to the sparse data available, and in recognition of
the variety of dressings in our unit, we aim to investigate
DSW dressings currently in use in the PLPBC. This trial
seeks to answer the following question: in pediatric
STSGs, which of the three DSW dressings currently in
use at our institution (Algisite™ M, Cuticerin™ and
Sorbact®) is superior in terms of pain and itch, wound
healing, ease of application and removal, scarring and
costs? The best-performing dressing will become our
preferred standard, against which we are likely to
subsequently repeat the trial as newer dressings be-
come available.The Pegg Leditschke Paediatric Burns Centre
The Pegg Leditschke Paediatric Burns Centre (PLPBC)
is the major pediatric burns centre for Queensland and
Northern New South Wales in Australia, serving a
population of approximately 4.5 million. The PLPBC
treats approximately 750 new burns annually. A total of
79 patients received split-thickness skin grafts in 2013.
The majority of patients have small areas requiring
grafting, and our preferred donor site is the thigh or
buttock. On occasion grafts from the adjacent skin are
used to combine donor and graft sites into a single
dressing site. Facial burns are preferentially treated
with scalp grafts whereas larger burns may require
using the back as a donor site.
The PLPBC promotes ‘bench to bedside, and back to
bench’ burns care. Clinical questions drive our research
efforts, the result of which alter clinical care and in turn
generate the next round of research questions. The
centre has research and prevention arms, as well a clin-
ical multidisciplinary team. The PLPBC has numerous
publications in pediatric burns across many different as-
pects of this care; laboratory, clinical burns care, patient
and family response to burn injury, prevention, rehabili-
tation, physio- and occupational therapy and procedural
pain control and distraction modalities.Methods/Design
Protocol and registration
This trial has approval from the Royal Children’s Hospital
Human Research Ethics Committee (approval number:
HREC/14/QRCH/36), and from the University of
Queensland Medical Research Ethics Committee (ap-
proval number: 2014000447). The methodology is speci-
fied in advance, documented in a protocol and has been
registered prior to recruitment commencing (Australia
and New Zealand Clinical Trials Register, identifier:
ACTRN12614000380695) [14]. The methods are sum-
marised here according to the revised Consolidated Stan-
dards for Reporting Trials (CONSORT) statement [15].
Design and setting
We have designed a single centre prospective parallel
randomised controlled trial with three treatment groups
(Figure 1). There is no control arm in the generally ac-
cepted sense, but we recognise many will view alginates
as a de facto control arm. Equipoise exists for this trial
as there is no generally accepted DSW dressing among
burns surgeons in general, and among the PLPBC sur-
geons in particular. We deem it unethical to have an in-
active control arm as our purpose is to find which of
three current dressings is superior.
The PLPBC will be moving to a new children’s hospital
in the same city in the middle of this trial (expected date
is late November 2014). All clinical staff will remain the
same, and we have systems in place to manage this tran-
sition with no disruption to acute services. While this
migration will be accompanied by a moratorium on
elective surgery, this will not be the case for children en-
rolled in the trial and requiring acute surgery. Their op-
erations and follow-up procedures and/or assessments
will not be delayed or postponed due to the migration.
Eligibility criteria for patients
From recruitment commencement, all patients of the
PLPBC requiring STSG will be consecutively considered
for inclusion, until recruitment is completed. Our unit
treats only pediatric patients, aged from birth to 15 years.
Regardless of the predicted size of the DSW, all children
undergoing STSG will be considered for inclusion.
Patients will be assessed for eligibility by their primary
surgeon or an investigator. If eligible, they will be
approached by a trained staff member not involved in
their primary care. Parent or caregiver informed con-
sent will be obtained and documented. Where appro-
priate, child assent will be documented (Additional
files 1 and 2).
Exclusion criteria include non-English speaking par-
ents or caregivers, as we will not be able to gather data
the following day by telephone. Also excluded are chil-
dren with a known cognitive impairment, and children
Assessment
Eligibility criteria
All patients requiring 
split -thickness skin 
grafting at PLPBC
Recruitment
≥28 patients in each arm
Trained staff (not primary 
clinician) explains nature 








Figure 1 Flow diagram of the trial. DSW, donor site wound;
PLPBC, Pegg Leditschke Paediatric Burns Centre.
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Communities, Child Safety and Disability Services. Only
thigh or buttock DSWs will be included.
Interventions
There is uniformity in the application of all three dress-
ings within the PLPBC; all are dressings that are already
in use. Three different DSW dressings will be used:
Algisite™ M, an alginate dressing (Smith & Nephew,
Hull, United Kingdom); Cuticerin™, a smooth acetate
gauze impregnated with water repellent ointment (pet-
rolatum, paraffin and Eucerite®) (Smith & Nephew, Hull,
United Kingdom) and Sorbact®, a gauze mesh coated
with a dialkylcarbamoyl chloride (DACC) and amorph-
ous hydrogel (Abigo Medical AB, Gothenburg, Sweden).
DACC is a synthetic fatty acid derivative. This dressing
is designed to cause a hydrophobic interaction between
bacteria and the dressing, lifting them from the wound
bed in a moist environment [16].
We no longer routinely use open weave paraffin gauze
or similar dressings directly on DSWs. The large mesh
spaces in these dressings can lead to incorporation dur-
ing re-epithelialisation which in turn can cause pain and
bleeding on dressing removal. Further, leaving such a
dressing on until spontaneous separation risks a per-
manent pattern on the DSW scar [17].
Surgical procedure
The grafting procedure will be performed with a
pneumatic dermatome (Zimmer Inc., Warsaw, Indi-
ana, United States), according to local practice. The
STSG will be harvested at between 0.005 and 0.008 of
an inch (0.13 to 0.20 mm), according to surgeon pref-
erence and the age of the patient. It is anticipated that
the majority will be taken with the dermatome set at
0.007 of an inch (0.18 mm), as this is the default local
setting. The particular dermatome used will be re-
corded, as will the ‘swipe number’ of the dermatome
blade in use at the time, the donor site and the sur-
geon harvesting the graft. A small lentiform biopsy
will be taken from the center of each graft, blocked,
cut and measured for graft thickness. Any remaining
donor skin at the conclusion of the case will be simi-
larly treated. This will allow more confidence regard-
ing DSW depth when analysing results.
Following harvesting, local anesthetic (bupivacaine
0.25% with epinephrine 1:200,000 AstraZeneca Pty Ltd,
North Ryde, NSW 2113, Australia) is applied directly
onto the wound up to the maximum safe dose calculated
from the weight of the child (2 to 2.5 mg/kg, depending
on the child and any co-morbidities). Post-harvest top-
ical application of local anesthetic was chosen rather
than pre-harvest infiltration in order to further standard-
ise the DSW, as infiltration was felt to be more variable.
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[18]. In longer cases donor sites may be temporarily
dressed with epinephrine and/or saline-soaked gauze
(1 mg/1,000 mL NaCl), with or without pressure dress-
ings, to facilitate hemostasis. The DSW is formally
dressed at the end of the case, following dressing of the
grafted site. One of the three dressings is applied directly
to the wound; followed by an absorbent second layer of
Allevyn™ and a Hypafix™ securement dressing (Smith &
Nephew, Hull, United Kingdom). The majority of pa-
tients are sent home the same day.
Wound treatment
Randomisation occurs immediately before the definitive
DSW dressing is applied. Where space between donor
sites permits (for example, between the left thigh and
right thigh), a second randomisation is permitted. Each
wound then constitutes its own study entity and will be
analysed separately.
The DSW dressing is taken down in clinic on the sev-
enth post-operative day. Our current standard dressing
following this first dressing change is Xeroform® (Covidien,
Mansfield Massachusetts, United States) 3% bismuth
tribromophenate occlusive petrolatum gauze, which will be
applied to all DSWs from this point. We expect the major-
ity of wounds to be healed or nearly healed at seven days,
from clinical observation. We have no experience using any
of the three study dressings on a DSW beyond this first
dressing change.
Clinics occur every weekday, and each patient is seen
twice weekly after the first dressing change. This is pred-
icated on ongoing treatment for the grafted site. By
reviewing the donor dressing on these occasions we will
avoid a requirement for additional clinic visits. Review-
ing the dressings every three days after the first week
replicates a real-world scenario and means that our re-
sults, if positive, will have clinical significance for this
outcome.
Co-interventions
Reinforcement of the primary dressing is permitted as
per standard clinical practice. In such cases the reinfor-
cing dressing, and the reason/s for applying it, will be re-
corded. On occasion children, parents or other health
care providers outside the hospital remove the dressing
within the first week. Should this occur, the study dress-
ing will be reapplied and reasons for the early removal
will be documented.
Interventions at dressing change, such as debridement,
cleansing or coverage with cling-film prior to review are
permitted in all arms, reflecting a real-life approach. In
the case of a suspected or diagnosed wound infection
the wound may be treated with antimicrobial agents
(povidone iodine and/or nanocrystalline silver dressings).Common definitions for superficial surgical site infec-
tions (SSI) are predicated on an incisional, rather than
excisional wound [19] and their appropriateness for
DSW infection is questionable. We have taken a clinical
approach based on the definition of a superficial SSI.
Diagnosis of wound infection in this trial is by agreement
of the treating clinician and a second burns surgeon.
Criteria used for defining wound infection are qualitative,
and include purulent discharge from the DSW surface;
serous or haemoserous discharge alone does not consti-
tute infection. Inflammation extending beyond the mar-
gins of the DSW at dressing change is another criterion. A
surface swab is inaccurate and has a long lead time, but
will nonetheless be performed for a colony count as it may
provide some quantitative data in support of the diagnosis.
A positive swab alone does not constitute an infection.
We do not perform punch biopsies of our patients in
clinic. As part of the dressing protocol these wounds will
all be photographed.
Standard analgesia will be provided to all children. For
larger total body surface area (TBSA) wounds it is our
practice to augment this with gabapentin and/or anti-
histamines in an effort to decrease itch. These medica-




There are two primary endpoints: pain, and time to re-
epithelialisation. Pain will be assessed at several time
points. Firstly, at four hours following completion of the
operation. This will allow measurement in day-case pa-
tients prior to their discharge. By taking these scores
face to face we hope to facilitate the telephone call the
following day. It is also an opportunity to clarify directly
with parents that we are scoring DSW pain, rather than
graft site pain. Secondly, at one day later via a telephone
call, or following ward review for inpatients. Thirdly, im-
mediately before premedication prior to removal of the
DSW dressing in clinic. Premedication will be with oxy-
codone 0.1 mg/kg orally (Mundipharma Pty Ltd, Sydney,
NSW 2000, Australia), and oral paracetamol 150 mg/kg
(sanofi-aventis Australia Pty Ltd, Macquarie Park, NSW
2113, Australia). Fourthly, at two minutes following re-
moval of the DSW dressing. The graft dressing will not
be taken down until after these scores are recorded. If a
dressing is reapplied, the recordings at time points two,
three and four above will be repeated for each subse-
quent change.
A variety of scales will be used for assessing pain, de-
termined by who is performing the assessment (observer,
parent or child), and by the age of the child. The face,
legs, activity, cry and consolability (FLACC) scale will
be used by nursing staff [20]. Where children are old
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used for patient self-reporting of pain [21]. We will
collect FPS-R data for children aged from three years,
recognising that data are sparse for children below the
age of five years [21]. Parents will use an 11-point
(0 to 10) numeric rating scale (NRS). This, rather than
a visual analogue scale, was chosen to facilitate the ac-
curacy of recording during a telephone call.
Re-epithelialisation is defined as over 95% wound heal-
ing and no requirement for further wound dressing.
Scabs or crusts are defined as unhealed areas. This end-
point is doubly assessed. In the clinic the treating doctor
assesses percentage re-epithelialisation. It is further
assessed from digital photography by an independent
surgeon blinded to the DSW dressing. Photographs will
be taken at each dressing change and at each subsequent
clinic visit for care. In the clinic a visual percentage re-
epithelialisation will be requested. The blinded obser-
ver will subsequently mark out the edges of the wound,
and any unhealed areas. Surface area computer map-
ping will then be used to determine percentage re-
epithelialisation. We will test concordance between
clinician assessment and computer mapping regarding
re-epithelialisation.
Secondary endpoints
Itch is a secondary endpoint. The Itch Man Scale will be
used for assessing itch. This scale has been validated in
children [22]. These assessments will occur at the same
time as the pain scores above. Itch will also be assessed
at the three, six and 12 month reviews. DSW appearance
at three, six and 12 months is a secondary endpoint.
This will be assessed in a number of ways: ultrasound
measurement of scar thickness; digital three-dimensional
photography and edge marking to determine computer-
mapped areas of scarring. This will be compared with
previous digital images; Patient and Observer Scar As-
sessment Scale (POSAS) [23]. We chose POSAS as this
has superior performance in a systematic review over
other scar assessment scales, and from a pragmatic view-
point is the scale PLPBC staff are most familiar with
[24]. It also seeks the opinions of the patient regarding
their scar, something we consider important. In practice
for many of our young children we use the parent opin-
ion. Where possible we ask both parent and patient.
There are some reliability data supporting the use of this
scale in children above the age of six years [25]. Below
this age caregiver opinion will be sought as a proxy for
the child.
Ease of dressing application and removal is a second-
ary endpoint. Setup time will not be recorded; times for
removal and reapplication of dressing will be recorded.
A numeric rating scale (0 to four) will be used to ascer-
tain opinions regarding ease of dressing removal at firstchange. Ease of dressing measurements in theatre are
confounded by lack of blinding, and by the variable
nature and size of the areas to be dressed. Ease of
dressing scores in clinic will focus primarily on the
ease with which the primary dressing is removed from
the skin surface.
Cost is a secondary endpoint. This will be assessed
using hospital pricing for the dressings used, and nurs-
ing time for dressing changes. Additional visits, where
required, will also be included in the cost analysis.
Routine visits will not be costed, since these are a stand-
ard part of treatment. Any additional treatments outside
of standard care, such as treatment for infection, will be
included in costing. A cost-utility analysis will not be
performed, as the site and nature of the burn wound
grafted will confound quality of life results. We will thus
not be able to isolate the DSW from the grafted site in
order to perform cost-utility on the DSW alone.Randomisation
Randomisation will occur in the operating theatre, im-
mediately prior to application of the DSW dressing. We
have used unrestricted randomisation, generated using
an online program (http://stattrek.com/) [26]. Random-
isation of participants will continue until each of the
study groups has a minimum of 28 participants reaching
the primary endpoints. Allocation concealment will be
via the use of sequentially numbered, sealed opaque en-
velopes pre-prepared by a third party.
Patients will be recruited into the trial when a decision
to graft is made following review of the burn injury. The
patient will be randomised intra-operatively, further sep-
arating recruitment and consent from randomisation.Blinding
The nature of the study mitigates against full blinding,
but some assessments can be blinded. Secondary dress-
ings for all patients are the same, so clinic staff will not
initially know which arm the patient is in. Clinic staff,
patients and parents are blinded for assessments of pain
and itch until the first dressing change. Following that
point, blinding is not possible for the remainder of the
pain and itch assessments as the dressing will have been
revealed.
One of the assessors of re-epithelialisation will be
blinded, as these assessments will take place using digital
photography. Details of the dressing will not be made
available to this assessor. Where there is discrepancy be-
tween these two observations, the blinded assessor will
be taken as the definitive assessment in an effort to over-
come performance bias. The assessments of scar appear-
ance will also be blinded, as assessors will have no
knowledge of the dressing used.
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The sample size calculation was derived from the pri-
mary outcomes. Dressings are changed every three days
after the first week, and we have used three days as a
minimum clinically important difference (MCID) for re-
epithelialisation. The standard deviation (SD) on DSW
healing, from our database, is four days. We have chosen
to power the study to 80%, with an α of 0.05, requiring
28 participants in each group. This sample size is also
adequate to determine an MCID of 2 (SD 2.5) in our
pain scores using the FLACC and the NRS.
We will use simple randomisation in order to
maintain the same degree of DSW dressing unpre-
dictability for each subject. Recruitment will con-
tinue until there are at least 28 participants in each
arm with primary outcome data. A two-year recruit-
ment period is anticipated, based upon the number
of eligible patients requiring grafting in our unit in
previous years.Data collection
A series of standardised case record forms have been de-
signed using Filemaker Pro 13 (Filemaker Inc., Santa
Clara, California, United States). These are loaded onto
tablets for use in theatre and in the clinic. These tablets
are a standard part of our data collection system already
in place, and staff are trained in their use.
Data are collected on baseline demographic and
patient condition characteristics, as well as the inter-
ventions used. Clinic and operative databases will be
married to the study database. Data entry will be by
clinic staff in the course of patient treatment. Discrep-
ancies will be resolved by discussion and by re-
checking the data. Where consensus is not possible
that field will be left empty.Data monitoring
Data are monitored weekly for completeness, and
reminders are sent to capture incomplete data. All re-
searchers spend a considerable amount of time in the
clinic and theatre, and will be closely associated with
data collection. We currently capture data on all pa-
tients seen in clinic; some of which is submitted to the
Australia and New Zealand Bi-national Burns Registry
(ANZ Bi-NBR) [27]. The data we collect are more de-
tailed than required for the ANZ Bi-NBR. Our current
data completeness rate for our databases is 100%. The
dressings we use are already a part of current practice
in our unit; therefore we have not set up a data safety
monitoring board for adverse effects. Our unit already
has a robust monitoring system, with a weekly team
meeting and a monthly morbidity meeting.Data analysis
All statistical analyses will be conducted using SPSS ver-
sion 22 (IBM Corporation, Armonk, New York, United
States). Demographic data will be analysed through de-
scriptive statistics and between-groups analyses using
analysis of variance (ANOVA) and/or non-parametric
equivalents where appropriate. Generalised linear models,
estimating variance appropriately for repeated measures
where required, will be used to determine whether there
are differences between groups in primary and secondary
outcomes. Changes in the intervention effects will be
examined with thickness of split skin graft, donor site
surface area and ease of dressing removal considered a
priori to be of potential interest. All data will be ana-
lysed as intention to treat (ITT) and per protocol, with
ITT considered the primary method. All tests will be
two-tailed and only those with a P value <0.05 will be
considered statistically significant.
Data storage
Data are backed up to a master file on a University of
Queensland server. This file is password protected, and
only available to the named researchers on the Human
Research Ethics Committee (HREC) approvals. On com-
pletion of the project, identifying data will be removed
from the record. The record will be kept in perpetuity in
order that these data may form a historical cohort if the
study is repeated with future dressings. De-identified
data may be made available to other researchers in fu-
ture to facilitate systematic reviews or meta-analyses. If
such data are requested, they will only be made available
following HREC review and approval.
Discussion
For such a commonly created wound, it is surprising
that there is no uniform dressing choice for DSWs [2,3].
There are a number of possible reasons for this: multiple
dressings may have equivalent efficacy; more attention is
focused on the grafted site, and the DSW is seen as a
secondary priority and there are a lack of reliable and
valid data regarding dressing choices.
While there are a number of trials and systematic re-
views, heterogeneity between studies makes direct com-
parisons difficult [10-13]. Tentative recommendations
support the use of dressings designed to create a moist
healing environment. The majority of studies have been
performed in adults. While it is tempting to extrapolate
adult data to a pediatric setting this may not be entirely
appropriate. Children’s skin is different to adults, and its
thickness varies by site, age and gender [28], therefore
trials in children may not have the same results as those
in adults.
PLPBC DSW dressings are determined largely by sur-
geon preference and dressing availability on the day of
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for two dressings against the active control of a calcium
alginate. With rigorous trial design, we hope to be able
to re-use this protocol in future should additional dress-
ings become available, which may offer advantages over
our chosen DSW dressing.
Our trial is intentionally pragmatic; we aim to repli-
cate current clinical practice as closely as possible. We
do not, for example, impose additional visits on partic-
ipants. We are looking for outcomes that are clinically
significant, and have chosen endpoints that are im-
portant to clinicians, and to patients and their families.
Where possible we have used blinded assessments to
second-read decisions in clinic. The scales we have chosen
have been previously validated in children, and we have
experience in all scales that will be used in this trial. This
is the first trial of DSW wound healing that incorporates
measurement of the harvested graft thickness into the
study protocol. This will enable us to correlate healing
with donor thickness.
Pain is a primary outcome of interest to parents and
clinicians alike, as well as to the patient. Data are
mixed on donor site pain, but the majority of studies
do agree that DSW pain is often more severe than
graft site pain. This is not a surprising finding given
the nature of the two wounds. A donor site more pain-
ful than its corresponding recipient site has an associ-
ated eponym; a positive Moriarty sign is said to be a
reassuring sign of impending graft take, rather than
graft failure [5].
Time to healing is a relevant primary outcome. Faster
re-epithelialisation allows us to re-harvest the donor site,
as well as limiting the timespan of this iatrogenic injury.
We try where possible to avoid meshed grafts, as the
final appearance is cosmetically inferior.
There are a paucity of data on the long-term appear-
ance of a DSW. Much scar studies have focused on
the grafted site and DSW scars as well. The Queens-
land climate is warm, and children often have their
thighs uncovered. In our climate the DSW may be
more on view than the grafted site itself, as our most
common burn injury is a scald to the anterior chest.
Scar appearance is a secondary outcome. Scarring is
related to the depth of injury, so to accommodate this
variable we will be measuring the depth of the STSG
at each donor site.Trial status
The first patient was randomised intra-operatively on 17
April 2014. As of 1 August 2014 we had recruited 36 pa-
tients. A total of 34 have been grafted and randomised
to one of the three dressings, with a further two awaiting
surgery.Additional files
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information and consent form.
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